- Home
- GOVX vs MEIP Comparison
GOVX vs MEIP Comparison
Compare GOVX & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- MEIP
- Stock Information
- Founded
- GOVX 2001
- MEIP 2000
- Country
- GOVX United States
- MEIP United States
- Employees
- GOVX N/A
- MEIP N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- MEIP Health Care
- Exchange
- GOVX Nasdaq
- MEIP Nasdaq
- Market Cap
- GOVX 15.5M
- MEIP 13.3M
- IPO Year
- GOVX N/A
- MEIP 2003
- Fundamental
- Price
- GOVX $0.95
- MEIP $2.80
- Analyst Decision
- GOVX Strong Buy
- MEIP Hold
- Analyst Count
- GOVX 5
- MEIP 1
- Target Price
- GOVX $12.40
- MEIP N/A
- AVG Volume (30 Days)
- GOVX 1.5M
- MEIP 13.3K
- Earning Date
- GOVX 08-05-2025
- MEIP 05-13-2025
- Dividend Yield
- GOVX N/A
- MEIP N/A
- EPS Growth
- GOVX N/A
- MEIP N/A
- EPS
- GOVX N/A
- MEIP N/A
- Revenue
- GOVX $5,591,576.00
- MEIP N/A
- Revenue This Year
- GOVX N/A
- MEIP N/A
- Revenue Next Year
- GOVX N/A
- MEIP N/A
- P/E Ratio
- GOVX N/A
- MEIP N/A
- Revenue Growth
- GOVX N/A
- MEIP 33.76
- 52 Week Low
- GOVX $0.73
- MEIP $1.46
- 52 Week High
- GOVX $11.18
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- GOVX 46.22
- MEIP 78.43
- Support Level
- GOVX $0.85
- MEIP $2.21
- Resistance Level
- GOVX $1.39
- MEIP $2.95
- Average True Range (ATR)
- GOVX 0.15
- MEIP 0.15
- MACD
- GOVX -0.02
- MEIP 0.05
- Stochastic Oscillator
- GOVX 18.52
- MEIP 81.48
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.